NASDAQ: CRSP · Biotechnology
Over the past week, CRISPR Therapeutics (CRSP) racked up about 79 mentions across Reddit, X and news, and the read is an Adanos Sell. The crowd averages 25% bullish across the tracked sources. Wall Street is more constructive, with 13 of 22 analysts rating CRSP a buy.
There is little buzz around CRSP this week and broad agreement on direction, which is why it reads as a Sell.
Wall Street’s 59% buy share sits next to a crowd that ranges from News at 21% to X at 28%. No other tracker puts the two side by side.
Across 22 analysts the consensus is a Buy: 13 buy calls against 0 sell, with an average 12-month price target of $87.56.
The Adanos signal blends each source’s bullish ratio, source breadth, buzz intensity and 3-day momentum. This week bullish sits just below the neutral line, momentum is cooling and the 3 sources broadly agree, so the read is a Sell.
Analysts sit 34 points above the crowd average of 25%, the professionals are more constructive than retail. The split is inside the crowd: X reads 28% bullish while News sits at 21%, a 7-point spread that single-source trackers miss.
Over the 30-day window, CRISPR Therapeutics (CRSP) buzz held subdued around 34.7 while the price drifted up 3.2% across the period. The chart tracks how social and news attention moved against end-of-day price. Average daily trading volume across the displayed trading days is 1.8M shares. Updated Oct 10, 2026. Over the last 7 trading days, CRSP lost 3.7%. Buzz activity in the recent week averaged 38.5 and was relatively stable, swinging between 33.5 and 44.8. Recent volume is in line with the 30-day average, reflecting steady institutional and retail participation. Daily crowd sentiment leaned bullish on 20 of the 21 days with directional mentions, shown as the green, grey and red breakdown bars below the chart.
Signal metrics use the latest 7 days; contributor and breadth context uses the 30-day chart window.
No Polymarket data for this stock this week.
Query sentiment for CRSP and 2110+ stocks from your terminal. Filter by source, timeframe and signal strength.
View CLIEmbed live CRSP sentiment on your own site with drop-in web components.
View WidgetsThis week’s sentiment from Adanos, with fundamentals and analyst consensus. A quick-reference snapshot for Oct 10, 2026.
| Adanos signal | Sell |
|---|---|
| Analyst consensus | Buy (13 / 9 / 0) |
| Crowd bullish (7d) | 25% |
| Avg price target | $87.56 |
| Most bullish source | X, 28% |
| Most bearish source | News, 21% |
| Sentiment spread | 7 pts |
| Mentions (7d) | 79 |
| Market cap | $4.88B |
| P/E · Forward P/E | n/a · 23.4 |
| EPS · Beta | -$4.74 · 1.8 |
| Revenue (TTM) | $13.4M · 0% margin |
| Industry | Biotechnology |
Based on aggregated sentiment from Reddit, X and News sources, CRISPR Therapeutics (CRSP) currently carries an Adanos sell signal with 93/100 conviction. The current cross-source average reads 25% bullish across 3 active sources. Those sources contribute 79 tracked mentions over the last 7 days. This is a sentiment-based reading, not financial advice.
Reddit discussion around CRISPR Therapeutics (CRSP) is fairly quiet with 12 mentions over the last 7 days; the 30-day context spans 18 tracked subreddits. The 7-day tone is 25% bullish; 3-day activity momentum is falling, suggesting cooling attention.
The crowd reads bearish on CRISPR Therapeutics (CRSP), averaging 25% bullish across 3 tracked sources over the last 7 days. The two ends of the range are X at 28% bullish and News at 21%, a 7-point spread. On the professional side, 13 of 22 analysts rate CRSP a buy.
Of the 22 analysts covering CRISPR Therapeutics (CRSP), 13 rate it a buy, 9 a hold and 0 a sell, for a buy consensus. The average price target is $87.56. That puts the street ahead of the crowd, which averages 25% bullish.
CRISPR Therapeutics (CRSP)'s cross-source average is bearish at 25% bullish. All 3 tracked sources lean bearish. Reddit reads 25% bullish, X reads 28% bullish and news coverage is the most negative at 21% bullish. The combined signal points to broad sell-side pressure with 93/100 conviction.
The cross-source average is bearish for CRISPR Therapeutics (CRSP) at 25% bullish. All 3 tracked sources lean bearish. The most bearish reading is news at 21% bullish. 3-day activity momentum is falling on Reddit and News, while x activity is rising. The sell signal carries 93/100 conviction.
X is the dominant discussion channel with 43 mentions (54% of total volume). News contributes 24 mentions and Reddit contributes 12 mentions. The cross-source average is bearish at 25% bullish, while x is the only source with rising 3-day activity. All 3 tracked sources lean bearish.
The Adanos signal blends bullish ratio, buzz score, source breadth and 3-day activity momentum into a single buy/sell reading. CRSP's sell signal at 93/100 conviction reflects a bearish cross-source average at 25% bullish. All 3 tracked sources lean bearish. It is a research shortcut, not financial advice.
The CRSP sentiment page is regenerated from the latest 7-day tracking window at each build. Data reflects the most recent Reddit posts, tweets and news articles available in the current publishing cycle.
Peers are ranked first by matching the Sell signal, then by the closest bullish ratio. Discussion activity breaks any remaining ties.
Every data point on this page comes from the Adanos sentiment APIs. Get a free API key and start querying Reddit, X, News and Polymarket sentiment programmatically.
Get Free API Key